Literature DB >> 11207017

Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods.

T Metso1, P Rytilä, C Peterson, T Haahtela.   

Abstract

Induced sputum is increasingly used to detect and monitor airway inflammation in respiratory diseases. However, the processing of sputum has been rather laborious for clinical practice. The aim of this study was to improve the practicality of induced-sputum studies by simplifying sample processing. Eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), neutrophil lipocalin (HNL) and myeloperoxidase (MPO) were used as biochemical markers of airway inflammation and the results of the study method were compared with a previously validated (reference) method. Induced sputum was obtained from 42 healthy controls, 10 subjects with acute respiratory infection, eight patients with chronic obstructive pulmonary disease (COPD) and 17 asthmatics. The sputum sample was divided into two parts and treated either: (i) by the reference method (released markers), where sputum was homogenized with dithiotreitol and centrifuged to yield cell-free supernatant and a cell pellet, or (ii) by the study method (total markers), where the cells were lysed after homogenization so that cell-associated markers were released and solubilized. For comparison, the four biochemical markers were measured in sputum supernatant and in sputum lysate. The differential cell count was performed from the cell pellet in the reference method. Repeatability was assessed in a group of 16 subjects. The effect of reagents and the recovery of assays were also evaluated. Released and total markers correlated well (ECP r(s)=0.80, P<0.0001; EPO r(s)=0.49, P<0.0001; HNL r(s)=0.87, P<0.0001; MPO r(s)=0.71, P<0.0001). Incubation with dithiotreitol and lysis reagent had no negative influence on marker assays. The within-subject variability of total ECP, MPO and HNL in both methods was small in two measurements taken I week apart. The study method, measuring total inflammatory markers, gave comparable results to the reference method, measuring released markers. In the study method the sputum processing was simplified, which may improve its applicability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207017     DOI: 10.1053/rmed.2000.0970

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  A halotyrosine antibody that detects increased protein modifications in asthma patients.

Authors:  Hongjun Jin; Teal S Hallstrand; Don S Daly; Melissa M Matzke; Parameswaran Nair; Diana J Bigelow; Joel G Pounds; Richard C Zangar
Journal:  J Immunol Methods       Date:  2013-12-02       Impact factor: 2.303

2.  Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.

Authors:  Leif Bjermer; Hans Bisgaard; Jean Bousquet; Leonardo M Fabbri; Andrew P Greening; Tari Haahtela; Stephen T Holgate; Cesar Picado; Joris Menten; S Balachandra Dass; Jonathan A Leff; Peter G Polos
Journal:  BMJ       Date:  2003-10-18

Review 3.  Oxidative stress and free radicals in COPD--implications and relevance for treatment.

Authors:  Wolfgang Domej; Karl Oettl; Wilfried Renner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-10-17

4.  Trigger of bronchial hyperresponsiveness development may not always need eosinophilic airway inflammation in very early stage of asthma.

Authors:  Yasushi Obase; Terufumi Shimoda; Reiko Kishikawa; Shigeru Kohno; Tomoaki Iwanaga
Journal:  Allergy Rhinol (Providence)       Date:  2016-01

5.  Lung Sound Analysis Provides A Useful Index For Both Airway Narrowing And Airway Inflammation In Patients With Bronchial Asthma.

Authors:  Terufumi Shimoda; Yasushi Obase; Yukio Nagasaka; Reiko Kishikawa; Sadahiro Asai
Journal:  J Asthma Allergy       Date:  2019-10-04

Review 6.  Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives.

Authors:  Noora Louhelainen; Marjukka Myllärniemi; Irfan Rahman; Vuokko L Kinnula
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

7.  Sputum myeloperoxidase in chronic obstructive pulmonary disease.

Authors:  Alling Zhu; Dehai Ge; Jingying Zhang; Yue Teng; Cheng Yuan; Mao Huang; Ian M Adcock; Peter J Barnes; Xin Yao
Journal:  Eur J Med Res       Date:  2014-03-03       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.